UNLABELLED: Daily oral tablet bisphosphonate therapy for Paget's disease of bone may cause serious upper gastrointestinal adverse events. A once-weekly alendronate 280 mg oral buffered solution was compared with an alendronate 40 mg/day tablet. While both were similarly effective, the tablet appeared to be better tolerated in this study. INTRODUCTION: Although daily doses of oral bisphosphonates are a generally safe and effective treatment for Paget's disease of bone (PDB), some patients may experience upper gastrointestinal adverse events (UGI AEs) or find the dosing requirements inconvenient and become noncompliant. A once-weekly (OW) oral dose of bisphosphonate in buffered solution (OBS) may be as effective, better tolerated, and more convenient. METHODS:Sixty-three patients were randomized to either alendronate (ALN) 280 mg OW OBS (n = 42) or an ALN 40 mg/day tablet (n = 21) during a 6-month, randomized, double-blind, active-controlled trial. The primary endpoint was the mean percent decrease in total serum alkaline phosphatase (total ALP) from baseline at 6 months. RESULTS: There were no significant differences in total ALP between groups during the 6-month period. There was a higher incidence of clinical AEs in the ALN 280 mg OW OBS (79%) vs. the ALN 40 mg/day tablet group (67%), including drug related AEs (48% and 10%, respectively), which led to study discontinuation (19.0% and 10%, respectively). CONCLUSIONS: Although ALN 280 mg OW OBS was similarly effective as ALN 40 mg/day in reducing total ALP in patients with PDB, the ALN 40 mg/day tablet appears to be better tolerated than ALN 280 mg OW OBS.
RCT Entities:
UNLABELLED: Daily oral tablet bisphosphonate therapy for Paget's disease of bone may cause serious upper gastrointestinal adverse events. A once-weekly alendronate 280 mg oral buffered solution was compared with an alendronate 40 mg/day tablet. While both were similarly effective, the tablet appeared to be better tolerated in this study. INTRODUCTION: Although daily doses of oral bisphosphonates are a generally safe and effective treatment for Paget's disease of bone (PDB), some patients may experience upper gastrointestinal adverse events (UGI AEs) or find the dosing requirements inconvenient and become noncompliant. A once-weekly (OW) oral dose of bisphosphonate in buffered solution (OBS) may be as effective, better tolerated, and more convenient. METHODS: Sixty-three patients were randomized to either alendronate (ALN) 280 mg OW OBS (n = 42) or an ALN 40 mg/day tablet (n = 21) during a 6-month, randomized, double-blind, active-controlled trial. The primary endpoint was the mean percent decrease in total serum alkaline phosphatase (total ALP) from baseline at 6 months. RESULTS: There were no significant differences in total ALP between groups during the 6-month period. There was a higher incidence of clinical AEs in the ALN 280 mg OW OBS (79%) vs. the ALN 40 mg/day tablet group (67%), including drug related AEs (48% and 10%, respectively), which led to study discontinuation (19.0% and 10%, respectively). CONCLUSIONS: Although ALN 280 mg OW OBS was similarly effective as ALN 40 mg/day in reducing total ALP in patients with PDB, the ALN 40 mg/day tablet appears to be better tolerated than ALN 280 mg OW OBS.
Authors: Frank Lanza; Bruce Sahba; Howard Schwartz; Steven Winograd; James Torosis; Hui Quan; Robert Reyes; Thomas Musliner; Anastasia Daifotis; Albert Leung Journal: Am J Gastroenterol Date: 2002-01 Impact factor: 10.864
Authors: T Schnitzer; H G Bone; G Crepaldi; S Adami; M McClung; D Kiel; D Felsenberg; R R Recker; R P Tonino; C Roux; A Pinchera; A J Foldes; S L Greenspan; M A Levine; R Emkey; A C Santora; A Kaur; D E Thompson; J Yates; J J Orloff Journal: Aging (Milano) Date: 2000-02
Authors: E Siris; R S Weinstein; R Altman; J M Conte; M Favus; A Lombardi; K Lyles; H McIlwain; W A Murphy; C Reda; R Rude; M Seton; R Tiegs; D Thompson; J R Tucci; A J Yates; M Zimering Journal: J Clin Endocrinol Metab Date: 1996-03 Impact factor: 5.958
Authors: S A Khan; J A Kanis; S Vasikaran; W F Kline; B K Matuszewski; E V McCloskey; M N Beneton; B J Gertz; D G Sciberras; S D Holland; J Orgee; G M Coombes; S R Rogers; A G Porras Journal: J Bone Miner Res Date: 1997-10 Impact factor: 6.741
Authors: P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang Journal: N Engl J Med Date: 1996-10-03 Impact factor: 91.245
Authors: Mohammad Shahnazari; Wei Yao; WeiWei Dai; Bob Wang; Sophi S Ionova-Martin; Robert O Ritchie; Daniel Heeren; Andrew J Burghardt; Daniel P Nicolella; Michael G Kimiecik; Nancy E Lane Journal: Bone Date: 2009-11-26 Impact factor: 4.398